Boundless Bio snags $105m Series B
Boundless Bio, a next-generation precision oncology company, has secured $105 million in Series B financing.
Boundless Bio, a next-generation precision oncology company, has secured $105 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination